Study Summary
This trial is testing a new drug for people with certain types of leukemia or myelodysplastic syndrome.
- Myelodysplastic Syndrome
- Acute Myeloid Leukemia (AML) in Relapse
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 6 Secondary · Reporting Duration: 28 Days
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
CB-5339
1 of 1
Experimental Treatment
60 Total Participants · 1 Treatment Group
Primary Treatment: CB-5339 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Wang, Feng, Shan Li, William M. Rosencrans, Kai‐Wen Cheng, Gordon M. Stott, Barbara Mroczkowski, and Tsui‐Fen Chou. 2022. “Sulforaphane Is Synergistic with CB‐5083 and Inhibits Colony Formation of Cb‐5083‐resistant HCT116 Cells”. Chemmedchem. Wiley. doi:10.1002/cmdc.202200030.
- 2020. "Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04402541.
Frequently Asked Questions
To what degree is CB-5339 hazardous to human health?
"Our experts at Power rated CB-5339 a 1 on the safety scale, due to this being an initial trial with limited evidence in terms of efficacy and safety." - Anonymous Online Contributor
Is enrollment still open for the trial?
"Clinicaltrials.gov has confirmed that this trial is actively recruiting participants; the initial posting was on June 8th 2020, with a recent edit occurring on July 27th 2022." - Anonymous Online Contributor
In what locations are this trial's efforts being conducted?
"At present, 8 medical centres are recruiting patients for this clinical trial. These locales span from Cleveland to Greenville and various other spots in-between; it is advisable to choose the nearest site of enrolment so as to abate any travel hardships." - Anonymous Online Contributor
How many individuals are participating in the experiment?
"To launch the trial, 60 eligible individuals are needed. Cleave Therapeutics, Inc., is managing this study across multiple sites including Cleveland Clinic and Case Comprehensive Cancer Center in Ohio as well as Weill Cornel Medical Center in New York City." - Anonymous Online Contributor